About this Research Topic
Lipid management has traditionally focused on controlling LDL, TG, and HDL plasma levels. However, the emphasis has shifted from quantity to quality in lipoprotein research. Aggressively reducing LDL-C alone does not eliminate cardiovascular risks, leading to the exploration of specific atherogenic LDL entities such as small-dense LDL, Lp(a), and electronegative LDL. Furthermore, the clinical significance of remnant lipoproteins, including VLDL and IDL, was overlooked until recently, when their vascular effects gained recognition. New evidence underscores that not all HDL particles are beneficial; some can be "dysfunctional" or even toxic. These insights primarily rely on clinical correlations, emphasizing the need to investigate the molecular mechanisms of these atherogenic lipoproteins in vitro and in vivo. This Research Topic can enhance our understanding of atherogenicity, potentially paving the way for new therapeutic discoveries.
A diverse array of lipoproteins, such as small-dense LDL, Lp(a), electronegative LDL (L1/L5, LDL(-)), remnant cholesterols (notably large VLDL and IDL), electronegative VLDL (V5), dysfunctional HDL, and electronegative HDL (H5), have emerged as prominent players in the realm of heightened atherogenicity. Establishing the pathogenic essence of these entities mandates a comprehensive exploration of their cellular and molecular mechanisms, alongside robust demonstrations of their atherogenic effects in vivo.
To draw a parallel with the renowned Koch's Postulates, which delineate the prerequisites for establishing a "causal relationship" between a microbe and a disease, a similar rigor is indispensable in the case of "atherogenic lipoproteins." In line with this framework, it is imperative to isolate these lipoproteins from a patient's plasma and confirm their atherogenic properties both in vitro in cells and in vivo in living organisms. With this theoretical foundation in mind, we extend a global invitation to researchers to present and deliberate upon the wealth of cell- and animal-based evidence pertaining to each putative atherogenic lipoprotein. We welcome contributions in the form of original research and review articles, recognizing that a thorough characterization of these pathogenic lipid entities is pivotal for advancing our comprehension of the disease and, subsequently, the development of innovative therapeutic interventions.
This collection is dedicated to advancing our grasp of atherogenic lipoproteins through the following key areas:
1. Mechanisms of Atherogenicity: Explore the cellular and molecular underpinnings of atherogenic lipoproteins, including small-dense LDL, Lp(a), electronegative lipoproteins, remnant lipoproteins, and dysfunctional HDL. We encourage manuscripts offering comprehensive insights into the biochemical and genetic factors driving atherogenesis.
2. In Vivo Evidence: Present compelling in vivo evidence illustrating the atherogenic effects of these lipoproteins, encompassing animal studies as well as ex vivo data obtained by clinical investigations.
3. Comparative Analyses: Investigate the relative atherogenic potential of various lipoprotein subtypes and their interactions in cardiovascular diseases. We invite articles shedding light on the nuanced significance of these lipoproteins.
4. Therapeutic Approaches: Examine potential therapeutic interventions aimed at addressing atherogenic lipoproteins. Authors are encouraged to propose innovative strategies to tackle clinical challenges.
5. Clinical Insights: Submissions delving into the clinical aspects of atherogenic lipoproteins, covering diagnosis and risk assessment are of utmost interest.
A diverse array of lipoproteins, such as small-dense LDL, Lp(a), electronegative LDL (L1/L5, LDL(-)), remnant cholesterols (notably large VLDL and IDL), electronegative VLDL (V5), dysfunctional HDL, and electronegative HDL (H5), have emerged as prominent players in the realm of heightened atherogenicity. Establishing the pathogenic essence of these entities mandates a comprehensive exploration of their cellular and molecular mechanisms, alongside robust demonstrations of their atherogenic effects in vivo.
To draw a parallel with the renowned Koch's Postulates, which delineate the prerequisites for establishing a "causal relationship" between a microbe and a disease, a similar rigor is indispensable in the case of "atherogenic lipoproteins." In line with this framework, it is imperative to isolate these lipoproteins from a patient's plasma and confirm their atherogenic properties both in vitro in cells and in vivo in living organisms. With this theoretical foundation in mind, we extend a global invitation to researchers to present and deliberate upon the wealth of cell- and animal-based evidence pertaining to each putative atherogenic lipoprotein. We welcome contributions in the form of original research and review articles, recognizing that a thorough characterization of these pathogenic lipid entities is pivotal for advancing our comprehension of the disease and, subsequently, the development of innovative therapeutic interventions.
This collection is dedicated to advancing our grasp of atherogenic lipoproteins through the following key areas:
1. Mechanisms of Atherogenicity: Explore the cellular and molecular underpinnings of atherogenic lipoproteins, including small-dense LDL, Lp(a), electronegative lipoproteins, remnant lipoproteins, and dysfunctional HDL. We encourage manuscripts offering comprehensive insights into the biochemical and genetic factors driving atherogenesis.
2. In Vivo Evidence: Present compelling in vivo evidence illustrating the atherogenic effects of these lipoproteins, encompassing animal studies as well as ex vivo data obtained by clinical investigations.
3. Comparative Analyses: Investigate the relative atherogenic potential of various lipoprotein subtypes and their interactions in cardiovascular diseases. We invite articles shedding light on the nuanced significance of these lipoproteins.
4. Therapeutic Approaches: Examine potential therapeutic interventions aimed at addressing atherogenic lipoproteins. Authors are encouraged to propose innovative strategies to tackle clinical challenges.
5. Clinical Insights: Submissions delving into the clinical aspects of atherogenic lipoproteins, covering diagnosis and risk assessment are of utmost interest.
Keywords: Atherogenicity, small-dense LDL, Lp(a), electronegative LDL, electronegative VLDL, electronegative HDL, remnant lipoproteins, dysfunctional HDL
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
